Cargando…
CDK4/6 inhibitor-SHR6390 exerts potent antitumor activity in esophageal squamous cell carcinoma by inhibiting phosphorylated Rb and inducing G1 cell cycle arrest
BACKGROUND: Cell cycle dysregulation is common in human malignancies, and CDK4/6 inhibitors targeting cell cycle have potential antitumor activity. SHR6390 is a novel small molecule inhibitor specifically targeting the CDK4/6 pathway. However, the role of SHR6390 in esophageal squamous cell carcinom...
Autores principales: | Wang, Jiayuan, Li, Qingqing, Yuan, Jiajia, Wang, Jingyuan, Chen, Zuhua, Liu, Zhentao, Li, Zhongwu, Lai, Yumei, Gao, Jing, Shen, Lin |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5457542/ https://www.ncbi.nlm.nih.gov/pubmed/28578693 http://dx.doi.org/10.1186/s12967-017-1231-7 |
Ejemplares similares
-
A mass balance study of [(14)C]SHR6390 (dalpiciclib), a selective and potent CDK4/6 inhibitor in humans
por: Zhang, Hua, et al.
Publicado: (2023) -
Evaluation of the Effect of Food on the Pharmacokinetics of SHR6390, An Oral CDK4/6 Inhibitor, in Healthy Volunteers
por: Liu, Yan-ping, et al.
Publicado: (2022) -
Preclinical characterization of SHR6390, a novel CDK 4/6 inhibitor, in vitro and in human tumor xenograft models
por: Long, Fei, et al.
Publicado: (2019) -
The Synergistic Effects of SHR6390 Combined With Pyrotinib on HER2+/HR+ Breast Cancer
por: Wang, Yukun, et al.
Publicado: (2021) -
Gimatecan exerts potent antitumor activity against gastric cancer in vitro and in vivo via AKT and MAPK signaling pathways
por: Chen, Zuhua, et al.
Publicado: (2017)